⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19973973 | 0.81 | — | — | |
| SCHEMBL815291 | 0.70 | — | — | |
| SCHEMBL6011630 | 0.70 | — | — | |
| SCHEMBL21731425 | 0.70 | — | — | |
| SCHEMBL8285795 | 0.70 | — | — | |
| SCHEMBL13033027 | 0.70 | — | — | |
| SCHEMBL1774204 | 0.70 | — | — | |
| SCHEMBL5433985 | 0.70 | — | — | |
| SCHEMBL8195841 | 0.69 | CRBN (0.33) | — | |
| SCHEMBL6042160 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-7082166-A | — | — | None | — | — | JP | disclosed |
| US-20220177521-A1 | PROCESS FOR THE PREPARATION OF DEGARELIX | Fresenius Kabi Ipsum S.R.L. (IT) | 2022-06-09 | — | — | US | disclosed |
| EP-3981781-A1 | PROCESS FOR THE MANUFACTURE OF DEGARELIX AND ITS INTERMEDIATES | Fresenius Kabi iPSUM S.r.l. (IT) | 2022-04-13 | — | — | EP | disclosed |
| CN-108779150-B | Preparation method of degarelix and intermediate thereof | 费森尤斯卡比依普莎姆责任有限公司 | 2022-03-29 | — | — | CN | disclosed |
| US-20220033443-A1 | PROCESS FOR THE MANUFACTURE OF DEGARELIX AND ITS INTERMEDIATES | Fresenius Kabi iPSUM S.r.l (IT) | 2022-02-03 | — | — | US | disclosed |
| EP-3935072-A1 | PROCESS FOR THE PREPARATION OF DEGARELIX | Fresenius Kabi iPSUM S.r.l. (IT) | 2022-01-12 | — | — | EP | disclosed |
| US-11168114-B2 | Process for the manufacture of degarelix and its intermediates | Fresenius Kabi iPSUM S.r.l (IT) | 2021-11-09 | — | — | US | disclosed |
| US-20200172577-A9 | PROCESS FOR THE MANUFACTURE OF DEGARELIX AND ITS INTERMEDIATES | Fresenius Kabi Ipsum S.R.L. (IT) | 2020-06-04 | — | — | US | disclosed |
| US-20180362588-A1 | PROCESS FOR THE MANUFACTURE OF DEGARELIX AND ITS INTERMEDIATES | FRESENIUS KABI IPSUM S R L (IT) | 2018-12-20 | — | — | US | disclosed |
| EP-3390427-A1 | PROCESS FOR THE MANUFACTURE OF DEGARELIX AND ITS INTERMEDIATES | Fresenius Kabi iPSUM S.r.l. (IT) | 2018-10-24 | — | — | EP | disclosed |
| WO-2017103275-A1 | PROCESS FOR THE MANUFACTURE OF DEGARELIX AND ITS INTERMEDIATES | FRESENIUS KABI ANTI-INFECTIVES S.R.L (IT) | 2017-06-22 | — | — | WO | disclosed |
| EP-1003774-A1 | GnRH ANTAGONISTS BEING MODIFIED IN POSITIONS 5 AND 6 | FERRING B.V. (NL) | 2000-05-31 | — | — | EP | disclosed |
| EP-0973801-A1 | GnRH ANTAGONISTS | FERRING B.V. (NL) | 2000-01-26 | — | — | EP | disclosed |
| WO-1998046635-A1 | GnRH ANTAGONISTS | FERRING BV (NL) | 1998-10-22 | — | — | WO | disclosed |
| WO-1998046634-A1 | GnRH ANTAGONISTS BEING MODIFIED IN POSITIONS 5 AND 6 | FERRING B.V. (NL) | 1998-10-22 | — | — | WO | disclosed |
| JP-H0782166-A | ANTISHOCK AGENT | TANABE SEIYAKU CO LTD | 1995-03-28 | — | — | JP | disclosed |
| EP-0470175-A1 | ENZYMATIC MEMBRANE METHOD FOR THE SYNTHESIS AND SEPARATION OF PEPTIDES | THE COCA-COLA COMPANY (US) | 1992-02-12 | — | — | EP | disclosed |